LIFECORE BIOMEDICAL, INC. \DE\
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Property, plant and equipment, net
- Property, plant and equipment, net
All property, plant and equipment is located in the United States. The following table presents the components of property, plant and equipment:
| March 31,2026 | December 31,2025 | |
|---|---|---|
| Land and land improvements | $3,491 | $3,491 |
| Buildings and building improvements | 82,062 | 82,021 |
| Machinery and equipment | 82,253 | 82,139 |
| Computer equipment and software | 9,064 | 7,852 |
| Furniture and fixtures | 1,422 | 1,422 |
| Construction in process | 7,839 | 9,539 |
| Property, plant, and equipment, gross | 186,131 | 186,464 |
| Less: accumulated depreciation | (60,618) | (59,160) |
| Property, plant, and equipment, net | $125,513 | $127,304 |
On January 7, 2025, the Company entered into an agreement for the sale of certain excess equipment. The aggregate purchase price was$17,000. Lifecore received$7,000 cash and paid fees of$752 at closing. Lifecore also accepted a note for the remainder of the proceeds (see note 4) and recorded current and noncurrent payables of$800 and$200, respectively, for selling fees due to a third-party broker. The note and the payables were each cash-settled in June 2025. The sale resulted in a $21,239 reduction in idle construction in process. The Company recorded a loss on the sale of the equipment of$6,400, which is included in loss on sale or disposal of assets, net of portion classified as cost of sales, within the statement of operations.
Depreciation expense for property, plant and equipment for thethree months ended March 31, 2026 and February 23, 2025 was$2,310 and $2,076, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.